Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse for at evaluere effektiviteten og sikkerheden af ​​bimekizumab hos undersøgelsesdeltagere med moderat til svær Hidradenitis Suppurativa (BE HEARD I)

1. oktober 2026 opdateret af: UCB Biopharma SRL

En fase 3, randomiseret, dobbeltblind, placebokontrolleret, multicenterundersøgelse, der evaluerer effektiviteten og sikkerheden af ​​bimekizumab hos undersøgelsesdeltagere med moderat til svær Hidradenitis Suppurativa

The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

505

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Campbelltown, Australien
        • Hs0003 30015
      • Carlton, Australien
        • Hs0003 30016
      • East Melbourne, Australien
        • Hs0003 30011
      • Kogarah, Australien
        • Hs0003 30017
      • Woolloongabba, Australien
        • Hs0003 30012
      • Brussels, Belgien
        • Hs0003 40004
      • Brussels, Belgien
        • Hs0003 40121
      • Leuven, Belgien
        • Hs0003 40002
      • Liège, Belgien
        • Hs0003 40060
      • Barrie, Canada
        • Hs0003 50233
      • Richmond Hill, Canada
        • Hs0003 50190
      • Saskatoon, Canada
        • Hs0003 50192
      • St. John's, Canada
        • Hs0003 50173
      • Surrey, Canada
        • Hs0003 50133
      • Aarhus N, Danmark
        • Hs0003 40127
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35233
        • Hs0003 50140
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85006
        • Hs0003 50175
    • California
      • Los Angeles, California, Forenede Stater, 90045
        • Hs0003 50161
      • San Diego, California, Forenede Stater, 92123
        • Hs0003 50220
    • Florida
      • North Miami Beach, Florida, Forenede Stater, 33162-4708
        • Hs0003 50205
      • Ormond Beach, Florida, Forenede Stater, 32174
        • Hs0003 50153
      • Tampa, Florida, Forenede Stater, 33613
        • Hs0003 50141
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30309
        • Hs0003 50210
      • Watkinsville, Georgia, Forenede Stater, 30677
        • Hs0003 50280
    • Kentucky
      • Murray, Kentucky, Forenede Stater, 42071
        • Hs0003 50425
    • Massachusetts
      • Beverly, Massachusetts, Forenede Stater, 01915
        • Hs0003 50198
      • Boston, Massachusetts, Forenede Stater, 02215
        • Hs0003 50146
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68144
        • Hs0003 50194
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89148
        • Hs0003 50208
    • New Jersey
      • East Windsor, New Jersey, Forenede Stater, 08520
        • Hs0003 50137
    • New York
      • New York, New York, Forenede Stater, 10003
        • Hs0003 50235
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27516
        • Hs0003 50151
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45219
        • Hs0003 50177
      • Columbus, Ohio, Forenede Stater, 43213
        • Hs0003 50138
    • Oklahoma
      • Tulsa, Oklahoma, Forenede Stater, 74135
        • Hs0003 50204
    • Pennsylvania
      • Hershey, Pennsylvania, Forenede Stater, 17033
        • Hs0003 50147
    • Rhode Island
      • Johnston, Rhode Island, Forenede Stater, 02919
        • Hs0003 50008
      • Providence, Rhode Island, Forenede Stater, 02903
        • Hs0003 50180
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37215
        • Hs0003 50142
    • Texas
      • Arlington, Texas, Forenede Stater, 76011
        • Hs0003 50201
      • Dallas, Texas, Forenede Stater, 75246
        • Hs0003 50166
      • San Antonio, Texas, Forenede Stater, 78213
        • Hs0003 50149
    • Washington
      • Seattle, Washington, Forenede Stater, 98101
        • Hs0003 50270
      • Amiens, Frankrig
        • Hs0003 40197
      • Angers, Frankrig
        • Hs0003 40342
      • Le Mans, Frankrig
        • Hs0003 40355
      • Nice, Frankrig
        • Hs0003 40132
      • Rouen, Frankrig
        • Hs0003 40318
      • Saint-Mandé, Frankrig
        • Hs0003 40246
      • Toulon, Frankrig
        • Hs0003 40285
      • Athens, Grækenland
        • Hs0003 40251
      • Athens, Grækenland
        • Hs0003 40253
      • Thessaloniki, Grækenland
        • Hs0003 40252
      • Breda, Holland
        • Hs0003 40351
      • Groningen, Holland
        • Hs0003 40292
      • Rotterdam, Holland
        • Hs0003 40264
      • Haifa, Israel
        • Hs0003 20089
      • Tel Aviv, Israel
        • Hs0003 20088
      • Catania, Italien
        • Hs0003 40261
      • Roma, Italien
        • Hs0003 40257
      • Roma, Italien
        • Hs0003 40263
      • Rozzano, Italien
        • Hs0003 40258
      • Terracina, Italien
        • Hs0003 40331
      • Torino, Italien
        • Hs0003 40330
      • Trondheim, Norge
        • Hs0003 40332
      • Bern, Schweiz
        • Hs0003 40337
      • Geneva, Schweiz
        • Hs0003 40406
      • Badalona, Spanien
        • Hs0003 40266
      • Las Palmas de Gran Canaria, Spanien
        • Hs0003 40294
      • Pontevedra, Spanien
        • Hs0003 40295
      • Seville, Spanien
        • Hs0003 40049
      • Valencia, Spanien
        • Hs0003 40230
      • Ankara, Tyrkiet (Türkiye)
        • Hs0003 40053
      • Antalya, Tyrkiet (Türkiye)
        • Hs0003 40270
      • Gaziantep, Tyrkiet (Türkiye)
        • Hs0003 40273
      • Istanbul, Tyrkiet (Türkiye)
        • Hs0003 40050
      • Istanbul, Tyrkiet (Türkiye)
        • Hs0003 40272
      • Izmir, Tyrkiet (Türkiye)
        • Hs0003 40271
      • Berlin, Tyskland
        • Hs0003 40325
      • Bochum, Tyskland
        • Hs0003 40248
      • Bonn, Tyskland
        • Hs0003 40327
      • Darmstadt, Tyskland
        • Hs0003 40288
      • Dresden, Tyskland
        • Hs0003 40324
      • Kiel, Tyskland
        • Hs0003 40249
      • Magdeburg, Tyskland
        • Hs0003 40357
      • Mainz, Tyskland
        • Hs0003 40174
      • München, Tyskland
        • Hs0003 40323
      • Münster, Tyskland
        • Hs0003 40177

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Participant must be at least 18 years of age, at the time of signing the informed consent. If a study participant is under the local age of consent and is at least 18 years of age, written informed consent will be obtained from both the study participant and the legal representative

  • Study participants must have a diagnosis of Hidradenitis Suppurativa (HS) based on clinical history and physical examination for at least 6 months prior to the Baseline visit

  • Study participant must have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla), 1 of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline visits

  • Study participant must have moderate to severe HS defined as a total of ≥5 inflammatory lesions (ie, number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline visits

  • Study participant must have had an inadequate response to a course of a systemic antibiotic for treatment of HS as assessed by the Investigator through study participant interview and review of medical history

  • A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of childbearing potential (WOCBP) OR
    2. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 20 weeks after the last dose of investigational medicinal product (IMP)

Exclusion Criteria:

  • Draining tunnel count of >20 at the Baseline Visit
  • Any other active skin disease or condition (eg, bacterial cellulitis, candida intertrigo, extensive condyloma) that may, in the opinion of the Investigator, interfere with the assessment of hidradenitis suppurativa (HS)
  • Study participant has a diagnosis of sarcoidosis, systemic lupus erythematosus, or active inflammatory bowel disease (IBD)
  • Primary immunosuppressive condition, including taking immunosuppressive therapy following an organ transplant, or has had a splenectomy
  • Female who is breastfeeding, pregnant, or plans to become pregnant during the study or within 20 weeks following the final dose of investigational medicinal product (IMP)
  • Active infection or history of certain infection(s)
  • Active tuberculosis (TB) infection, latent TB infection, high risk of exposure to TB infection, current or history of nontuberculous mycobacterium (NTM) infection
  • Concurrent malignancy. Study participants with a history of malignancy within the past 5 years prior to the Screening Visit are excluded, EXCEPT if the malignancy was a cutaneous squamous or basal cell carcinoma, or in situ cervical cancer that has been treated and is considered cured
  • History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease
  • Known hypersensitivity to any components of bimekizumab or comparative drugs as stated in this protocol
  • Concomitant and prior medication restrictions
  • Myocardial infarction or stroke within the 6 months prior to the Screening Visit
  • Study participant has the presence of active suicidal ideation, or positive suicide behavior using the "Screening" version of the electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
  • Presence of moderately severe major depression or severe major depression
  • Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Bimekizumab dosing regimen 1

Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.

Subjects will receive bimekizumab at pre-specified time-points.

Andre navne:
  • UCB4940
Eksperimentel: Bimekizumab dosing regimen 2

Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.

Subjects will receive bimekizumab at pre-specified time-points.

Andre navne:
  • UCB4940
Eksperimentel: Bimekizumab dosing regimen 3

Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.

Subjects will receive bimekizumab at pre-specified time-points.

Andre navne:
  • UCB4940
Placebo komparator: Placebo Group

Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.

Subjects will receive bimekizumab at pre-specified time-points.

Andre navne:
  • UCB4940

Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.

Andre navne:
  • PBO

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16
Tidsramme: Week 16

HiSCR50 was defined as at least a 50 percent (%) reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data are imputed using multiple imputation with Markov Chain Monte Carlo (MCMC) method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an adverse event (AE) or lack of efficacy. Percentage of participants shown do not account for model effects using the logistic regression model.

Week 16

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16
Tidsramme: Week 16

HiSCR75 was defined as at least a 75% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentage of participants shown do not account for model effects using the logistic regression model.

Week 16
Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
Tidsramme: Baseline, Week 16

The DLQI is a patient-reported questionnaire designed for use in adult participants with skin diseases and Hidradenitis Suppurativa (HS). The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect patients' health related quality of life (HRQoL), with a recall period of 7 days. This instrument asks participants 10 questions about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The scoring of each answer for the DLQI is on a scale range of 0 (not at all) to 3 (very much). The DLQI total score was calculated by adding the score of each question. The maximum score is 30, and the minimum score is 0. The higher the score, the more quality of life is impaired. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data.

Baseline, Week 16
Absolute Change From Baseline in Worst Skin Pain Score at Week 16
Tidsramme: Baseline, Week 16

Absolute change from Baseline in Worst Skin Pain score at Week 16 was assessed using the worst skin pain item in the Hidradenitis Suppurativa Symptom Daily Diary (HSSDD). Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The worst skin pain score was derived from the weekly average of daily scores, defined as the sum of the scored item over the course of the study week divided by the number of days in which the item was completed, relative to each respective visit date. Intermittent missing data are imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data. Mean values shown do not account for model effects using the ANCOVA model.

Baseline, Week 16
Percentage of Participants Achieving Worst Skin Pain Response at Week 16
Tidsramme: Week 16

Skin pain response at Week 16, as assessed by "worst skin pain" item in HSSDD, was defined as an improvement in weekly worst skin pain score of at least 3 points versus Baseline. Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Worst skin pain score was derived from weekly average of daily scores (sum of scored item over study week/number of days in which item completed, relative to each respective visit). Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Weekly pain scores were imputed and then dichotomized to obtain response status. Participants who experienced an intercurrent event were treated as non-responders following the intercurrent event. Percentage of participants shown do not account for model effects using logistic regression model.

Week 16
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
Tidsramme: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety Follow-Up [SFU] period).

From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study
Tidsramme: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)

A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical events. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period).

From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study
Tidsramme: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). TEAEs leading to discontinuation of the study are reported.

From Baseline (Day 1) until Safety Follow-Up (up to Week 71)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: UCB Cares, 001 844 599 2273

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. februar 2020

Primær færdiggørelse (Faktiske)

7. april 2022

Studieafslutning (Faktiske)

19. februar 2023

Datoer for studieregistrering

Først indsendt

23. januar 2020

Først indsendt, der opfyldte QC-kriterier

23. januar 2020

Først opslået (Faktiske)

27. januar 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

26. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. oktober 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • HS0003
  • 2019-002550-23 (EudraCT nummer)
  • 2019 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

IPD-delingstidsramme

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

IPD-delingsadgangskriterier

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .